Full-Time

Regulatory Compliance Director

Posted on 9/10/2025

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$188.2k - $349.4k/yr

+ Discretionary annual bonus

Indianapolis, IN, USA

Hybrid

Three days on-site per week required.

US Top Secret Clearance Required

Category
Legal & Compliance (2)
,
Required Skills
Risk Management
Requirements
  • Education: Doctor of Jurisprudence from an ABA-accredited law school, licensed to practice law in one or more of the 50 states.
  • Professional experience: preferably at least 8-10 years’ experience practicing law at a large- to medium-sized law firm or within a corporate law department; practice should include areas of specialization in FDA regulatory law, with a focus on advertising and promotion; substantial industry experience also considered.
Responsibilities
  • Develop and implement regulatory strategies for advertising and promotional materials to ensure compliance with FDA regulations and other applicable guidelines.
  • Assess the impact of labeling language on promotional strategies to ensure compliance and alignment with commercial objectives.
  • Work collaboratively throughout the organization in a leadership, advisory, and facilitative capacity utilizing interdepartmental teams and systems to achieve compliance, quality improvement and risk management goals and objectives.
  • Develop an in-depth working knowledge of the products, pipeline, market and business model and apply this knowledge in managing direct reports and in the delivery of sound and practical counsel and advice focused on regulatory compliance.
  • Partner with Roche’s sales, marketing, and other commercial teams, to develop and implement the effective sale, distribution, marketing and advertising of Roche’s product portfolio in the U.S. by providing well-reasoned legal advice and practical and creative solutions to complex regulatory issues in support of business objectives.
  • Collaborate with, support and provide regulatory guidance and expertise to Roche business stakeholders in the assessment and implementation of third-party collaborations and partnering.
  • Collaborate with the RDC US Chief Compliance Officer to support Roche’s compliance programs.
  • Support and enable company compliance with policies, procedures, and code of conduct.
  • Recruit, develop, support and manage a team of high performing regulatory compliance professionals and provide guidance and coaching in developing the team’s skills and knowledge.
  • Sponsor and support various team projects and initiatives, including making continuous improvements to commercial processes and liaising with business partners to assist in creating or improving relevant policies.
  • Help set priorities for the Roche US Commercial Affiliate Legal & Compliance department and actively engage as an advisor and leader within the department and across the organization.
Desired Qualifications
  • In-depth knowledge of FDA regulations and familiarity with FTC regulations related to advertising and promotion.
  • Demonstrated experience in medical device advertising and industry best practices with deep understanding of regulatory frameworks that affect medical device advertising and marketing.
  • Experience reviewing and providing compliance counsel on advertising, marketing, and/or promotion for prescription drugs, biologics, or medical devices.
  • Strong understanding of the regulatory landscape and the ability to provide strategic guidance to cross-functional teams.
  • Must have strong leadership skills to inspire, empower, and develop regulatory professionals with a desire to coach and develop the team.
  • Previous experience managing direct reports, stakeholders and/or cross-functional teams to successfully complete objectives/projects.
  • Excellent communication and interpersonal skills, with ability to effectively collaborate with internal and external stakeholders.
  • Willingness and ability to deliver a consistent message in the face of pressure or adversity.
  • Ability to encourage transparent and connected culture between the Legal and Compliance Department and business stakeholders.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • CT-388 targets double-digit share in obesity market alongside Novo Nordisk and Lilly.
  • PathAI $750M acquisition scales AI digital pathology globally by late 2026.
  • Elecsys pTau217 Alzheimer's blood test launches in CE markets from July 2026.

What critics are saying

  • Rituxan patent expiry lets Sandoz biosimilars slash 40% lymphoma share in 6-12 months.
  • Swiss franc 12% rise compresses US 55% revenues as hedges expire in 6-18 months.
  • US IRA forces 60-80% discounts on Herceptin, Avastin from 2028, cutting $4B cashflow.

What makes Roche unique

  • Roche integrates pharmaceuticals and diagnostics via 1991 PCR acquisition from Cetus.
  • 1990 Genentech majority stake pioneered oncology antibodies like Herceptin and Rituxan.
  • Personalized healthcare strategy couples diagnostics to targeted therapies since 2009 full acquisition.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE